Notice
8 Aug 2025
healthcare, fda, bioequivalence, anda, iron sucrose, drug guidance
💉FDA Draft Guidance on Iron Sucrose and Bioequivalence for Industry
The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a revised draft guidance for industry entitled "Draft Guidance on Iron Sucrose." This revised draft guidance, when finalized, will provide product-specific recommendations on, among other things, the design of bioequivalence (BE) studies to support abbreviated new drug applications (ANDAs) for iron sucrose intravenous injectable.
Learn More